M&A / Deals GSK ends dementia alliance with Alector after setbacks PharmaphorumGSK's alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results.NeuroscienceRead full story pharminent July 9, 2026 (Last updated: July 10, 2026) Pharmaphorum GSK’s alliance with Alector to develop two drug candidates for dementia has been terminated in the wake of disappointing clinical trial results. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA freezes CRL trove as ‘radical transparency’ push hits speedbumpNext: AstraZeneca, Ionis drug fails big heart disease study in major setback Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
